G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting


You May Also Like

Melinta Therapeutics Reports Second Quarter 2018 Financial Results

Solid Performance from New Product Launches VabomereTM Granted NTAP Status by CMS Strengthened Financial Position ...

John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

MORRISVILLE, N.C., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully ...